What are the risks associated with warfarin for AF in an ICH survivor?
In a decision analysis which modeled warfarin for AF in an ICH survivor, avoiding warfarin increased quality-adjusted life years by 1.9, compared with 0.3 for deep ICH. In lobar ICH, avoiding warfarin increased quality-adjusted life years by 1.9, compared with 0.3 for deep ICH; the authors concluded that anticoagulation for AF should not be offered to patients with lobar ICH and only to survivors of deep ICH if the risk of ischemic events was high (> However, real-world observational studies suggest that anticoagulation might reduce mortality and ischemic complications, without an unacceptable increase in ICH.